N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
    1.
    发明授权
    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands 失效
    N-苯基吡咯胍衍生物作为黑皮质素受体配体

    公开(公告)号:US07186748B2

    公开(公告)日:2007-03-06

    申请号:US10484444

    申请日:2002-08-06

    IPC分类号: A61K31/402 C07D207/335

    摘要: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.

    摘要翻译: 本发明提供了作为黑皮质素受体的配体和/或用于治疗黑皮质素系统中的病症的通式(I)的新化合物:其中X是(CH 2) / SUB>其中n为0,1或2; R 1,R 2,R 3,R 4和R 5可以是 羟基,烷基磺酰氧基,氰基,硝基,三卤代烷基,磺基或方案1中给出的结构之一;其中R 1,R 2, 或R 1,R 2,R 3,R 4和R 5中的两个, 可以一起形成亚甲二氧基或亚乙二氧基部分; R 6,R 7,R 8和R 9相同或不同,并且选自氢, 卤素,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基,羟基,具有0,1或2个碳原子的胺(伯,仲或叔),氰基,硝基,三卤代烷基,酰胺或磺基,和z 显示残基与苯基或吡咯环的连接点; 及其药理学活性盐。

    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
    2.
    发明授权
    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands 失效
    N-苯基吡咯胍衍生物作为黑皮质素受体配体

    公开(公告)号:US07442807B2

    公开(公告)日:2008-10-28

    申请号:US11374956

    申请日:2006-03-15

    摘要: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.

    摘要翻译: 本发明提供了作为黑皮质素受体的配体和/或用于治疗黑皮质素系统中的病症的通式(I)的新化合物:其中X是(CH 2) / SUB>其中n为0,1或2; R 1,R 2,R 3,R 4和R 5可以是 羟基,烷基磺酰氧基,氰基,硝基,三卤代烷基,磺基或方案1中给出的结构之一;其中R 1,R 2, 或R 1,R 2,R 3,R 4和R 5中的两个, 可以一起形成亚甲二氧基或亚乙二氧基部分; R 6,R 7,R 8和R 9相同或不同,并且选自氢, 卤素,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基,羟基,具有0,1或2个碳原子的胺(伯,仲或叔),氰基,硝基,三卤代烷基,酰胺或磺基,和z 显示残基与苯基或吡咯环的连接点; 及其药理学活性盐。

    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
    4.
    发明申请
    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands 审中-公开
    N-苯基吡咯胍衍生物作为黑皮质素受体配体

    公开(公告)号:US20090018183A1

    公开(公告)日:2009-01-15

    申请号:US12232399

    申请日:2008-09-17

    IPC分类号: A61K31/40 A61P3/00 A61P25/00

    摘要: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.

    摘要翻译: 本发明提供了作为黑皮质素受体配体和/或用于治疗黑皮质素系统中的病症的通式(I)的新化合物:其中X是(CH 2)n,其中n是0,1或2; R 1,R 2,R 3,R 4和R 5可以相同或不同,并且选自氢,卤素,具有1-5个碳原子的烷基,具有1至5个碳原子的烷氧基,羟基,烷基磺酰氧基,氰基,硝基,三卤代烷基,磺基 或方案1中给出的结构之一; 或者R 1,R 2,R 3,R 4和R 5中的两个可以一起形成亚甲二氧基或亚乙二氧基部分; R 6,R 7,R 8和R 9相同或不同,并且选自氢,卤素,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基,羟基,具有0,1 或2个碳原子,氰基,硝基,三卤代烷基,酰胺或磺基,z表示残基与苯基或吡咯环的连接点; 及其药理学活性盐。

    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
    5.
    发明申请
    N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands 失效
    N-苯基吡咯胍衍生物作为黑皮质素受体配体

    公开(公告)号:US20060148798A1

    公开(公告)日:2006-07-06

    申请号:US11374956

    申请日:2006-03-15

    摘要: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.

    摘要翻译: 本发明提供了作为黑皮质素受体的配体和/或用于治疗黑皮质素系统中的病症的通式(I)的新化合物:其中X是(CH 2) / SUB>其中n为0,1或2; R 1,R 2,R 3,R 4和R 5可以是 羟基,烷基磺酰氧基,氰基,硝基,三卤代烷基,磺基或方案1中给出的结构之一;其中R 1,R 2, 或R 1,R 2,R 3,R 4和R 5中的两个, 可以一起形成亚甲二氧基或亚乙二氧基部分; R 6,R 7,R 8和R 9相同或不同,并且选自氢, 卤素,具有1至5个碳原子的烷基,具有1至5个碳原子的烷氧基,羟基,具有0,1或2个碳原子的胺(伯,仲或叔),氰基,硝基,三卤代烷基,酰胺或磺基,和z 显示残基与苯基或吡咯环的连接点; 及其药理学活性盐。

    METHOD AND APPARATUS FOR CONTROLLING TURBINE EFFICIENCY
    8.
    发明申请
    METHOD AND APPARATUS FOR CONTROLLING TURBINE EFFICIENCY 审中-公开
    控制涡轮机效率的方法和装置

    公开(公告)号:US20120159947A1

    公开(公告)日:2012-06-28

    申请号:US13202361

    申请日:2009-02-19

    IPC分类号: F02B37/12 F02B37/24

    摘要: A method of controlling turbine efficiency in a turbo unit provided on an internal combustion engine includes providing a flow of gas in an area upstream a turbine at a direction different to the flow of exhaust gases in the same area, regulating the flow by a valve, and controlling the valve from a control unit having at least boost pressure and/or EGR flow as input parameters.

    摘要翻译: 在内燃机上设置的涡轮机单元的涡轮机效率的控制方法包括:在与涡轮机的上游侧不同的方向,在与涡轮机上游的区域相同的区域内设置气体流,通过阀调节流量, 并且从具有至少增压压力和/或EGR流量的控制单元控制阀门作为输入参数。

    Separation structure
    10.
    发明授权

    公开(公告)号:US07833478B2

    公开(公告)日:2010-11-16

    申请号:US11871614

    申请日:2007-10-12

    IPC分类号: G01N9/30 G01N33/00 F16K17/36

    摘要: A centrifugal-based microfluidic device (1) that comprises a hydrophilic microchannel structure (2) in which there is a A) a separation microcavity I (4) that comprises i) a liquid inlet I (5), and ii) a liquid outlet I (6) that is at a level below the level of liquid inlet I (5) and above the level of the bottom (8) of the microcavity (4) thereby defining a lower part (4b) and an upper part (4a) of the microcavity (4), and B) a microconduit I (17) that has an inlet end I (16) directly connected to liquid outlet I (6), and an outlet end I (18) that is at a lower level than inlet end I (6). A capillary valve I (24) is associated with microconduit I (17). The flow direction through liquid outlet I (6) is directed upwards and/or liquid outlet I (6) is placed in a downwardly turned part of an inner wall of the separation microcavity (4), and/or the part of microconduit I (17) next to liquid outlet I (6) is directed upwards.